FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109023079> ?p ?o ?g. }

• W3109023079 abstract "Abstract Background Optimal dual antiplatelet therapy in high bleeding risk (HBR) patients with acute coronary syndromes (ACS) remains debated. Although current guidelines recommend the use of potent P2Y12 inhibitors in these patients (according to the labeled indications), clopidogrel is frequently used in clinical practice based on a perceived advantage in terms of safety in the HBR population. Purpose We sought to investigate the use of clopidogrel versus ticagrelor in consecutive HBR ACS patients and their impact on ischemic and bleeding events at 1 year. Methods ACS patients enrolled in the START-ANTIPLATELET registry with at least 1 HBR criterion were included in the present analysis and stratified according to DAPT type (clopidogrel versus ticagrelor). The primary endpoint was net adverse clinical endpoint (NACE), defined as a composite of all-cause death, myocardial infarction, stroke, and major bleeding. The secondary endpoints were major adverse cardiac and cerebral events (MACE), defined as a composite of all-cause death, myocardial infarction and stroke, each individual component of NACE and MACE, and target vessel revascularization. Results Among a total of 1,209 patients with 1-year follow-up in the registry, 383 patients were considered at HBR, of whom 174 (45.4%) were on clopidogrel and 209 (54.6%) on ticagrelor. Clopidogrel was more likely to be administered in patients at increased ischemic and bleeding risk, while ticagrelor in those undergoing percutaneous coronary intervention. Mean DAPT duration was longer in the ticagrelor group than in the clopidogrel group (10.40±4.29 versus 9.35±5.4; p-value=0.03). At 1-year follow-up, the risk of NACE and MACE events was significantly higher in the clopidogrel than in the ticagrelor group (NACE: HR 1.82; 95% CI 1.07–3.09; p-value=0.02; MACE: HR 1.83; 95% CI 1.04–3.24; p-value=0.03) (Figure). After multivariate adjustment for clinical and procedural characteristics, no difference in NACEs nor MACEs was observed between patients on clopidogrel versus ticagrelor (NACE: adjusted HR 1.27; 95% CI 0.71–2.27; p-value=0.42; MACE: adjusted HR 1.19; 95% CI 0.63–2.24; p-value=0.59) (Figure). Age, number of HBR criteria, and mean DAPT duration were independent predictors of NACEs. Conclusions In a real-world ACS registry, approximately 50% of patients are at HBR and frequently treated with clopidogrel. In HBR ACS patients, no difference was observed in ischemic and bleeding events between clopidogrel and ticagrelor after adjustment for potential confounders. Kaplan-Meier curves at 1-year follow-up. Funding Acknowledgement Type of funding source: None" @default.
• W3109023079 created "2020-12-07" @default.
• W3109023079 creator A5000200390 @default.
• W3109023079 creator A5003292078 @default.
• W3109023079 creator A5006406707 @default.
• W3109023079 creator A5008150148 @default.
• W3109023079 creator A5008290902 @default.
• W3109023079 creator A5025539088 @default.
• W3109023079 creator A5027649822 @default.
• W3109023079 creator A5028646700 @default.
• W3109023079 creator A5033373672 @default.
• W3109023079 creator A5043856648 @default.
• W3109023079 creator A5054188515 @default.
• W3109023079 creator A5055583365 @default.
• W3109023079 creator A5067848534 @default.
• W3109023079 creator A5068374739 @default.
• W3109023079 creator A5070057174 @default.
• W3109023079 creator A5075635455 @default.
• W3109023079 date "2020-11-01" @default.
• W3109023079 modified "2023-10-14" @default.
• W3109023079 title "Ticagrelor versus Clopidogrel in high bleeding risk patients presenting with Acute Coronary Syndromes: insights from the multicenter START-ANTIPLATELET registry" @default.
• W3109023079 doi "https://doi.org/10.1093/ehjci/ehaa946.1730" @default.
• W3109023079 hasPublicationYear "2020" @default.
• W3109023079 type Work @default.
• W3109023079 sameAs 3109023079 @default.
• W3109023079 citedByCount "0" @default.
• W3109023079 crossrefType "journal-article" @default.
• W3109023079 hasAuthorship W3109023079A5000200390 @default.
• W3109023079 hasAuthorship W3109023079A5003292078 @default.
• W3109023079 hasAuthorship W3109023079A5006406707 @default.
• W3109023079 hasAuthorship W3109023079A5008150148 @default.
• W3109023079 hasAuthorship W3109023079A5008290902 @default.
• W3109023079 hasAuthorship W3109023079A5025539088 @default.
• W3109023079 hasAuthorship W3109023079A5027649822 @default.
• W3109023079 hasAuthorship W3109023079A5028646700 @default.
• W3109023079 hasAuthorship W3109023079A5033373672 @default.
• W3109023079 hasAuthorship W3109023079A5043856648 @default.
• W3109023079 hasAuthorship W3109023079A5054188515 @default.
• W3109023079 hasAuthorship W3109023079A5055583365 @default.
• W3109023079 hasAuthorship W3109023079A5067848534 @default.
• W3109023079 hasAuthorship W3109023079A5068374739 @default.
• W3109023079 hasAuthorship W3109023079A5070057174 @default.
• W3109023079 hasAuthorship W3109023079A5075635455 @default.
• W3109023079 hasConcept C126322002 @default.
• W3109023079 hasConcept C127413603 @default.
• W3109023079 hasConcept C164705383 @default.
• W3109023079 hasConcept C168563851 @default.
• W3109023079 hasConcept C203092338 @default.
• W3109023079 hasConcept C2777698277 @default.
• W3109023079 hasConcept C2777849778 @default.
• W3109023079 hasConcept C2780400711 @default.
• W3109023079 hasConcept C2780645631 @default.
• W3109023079 hasConcept C2780739214 @default.
• W3109023079 hasConcept C2780890252 @default.
• W3109023079 hasConcept C2908647359 @default.
• W3109023079 hasConcept C500558357 @default.
• W3109023079 hasConcept C71924100 @default.
• W3109023079 hasConcept C78519656 @default.
• W3109023079 hasConcept C99454951 @default.
• W3109023079 hasConceptScore W3109023079C126322002 @default.
• W3109023079 hasConceptScore W3109023079C127413603 @default.
• W3109023079 hasConceptScore W3109023079C164705383 @default.
• W3109023079 hasConceptScore W3109023079C168563851 @default.
• W3109023079 hasConceptScore W3109023079C203092338 @default.
• W3109023079 hasConceptScore W3109023079C2777698277 @default.
• W3109023079 hasConceptScore W3109023079C2777849778 @default.
• W3109023079 hasConceptScore W3109023079C2780400711 @default.
• W3109023079 hasConceptScore W3109023079C2780645631 @default.
• W3109023079 hasConceptScore W3109023079C2780739214 @default.
• W3109023079 hasConceptScore W3109023079C2780890252 @default.
• W3109023079 hasConceptScore W3109023079C2908647359 @default.
• W3109023079 hasConceptScore W3109023079C500558357 @default.
• W3109023079 hasConceptScore W3109023079C71924100 @default.
• W3109023079 hasConceptScore W3109023079C78519656 @default.
• W3109023079 hasConceptScore W3109023079C99454951 @default.
• W3109023079 hasLocation W31090230791 @default.
• W3109023079 hasOpenAccess W3109023079 @default.
• W3109023079 hasPrimaryLocation W31090230791 @default.
• W3109023079 hasRelatedWork W10539617 @default.
• W3109023079 hasRelatedWork W18617680 @default.
• W3109023079 hasRelatedWork W2862113 @default.
• W3109023079 hasRelatedWork W3142333 @default.
• W3109023079 hasRelatedWork W4447781 @default.
• W3109023079 hasRelatedWork W4564605 @default.
• W3109023079 hasRelatedWork W7331692 @default.
• W3109023079 hasRelatedWork W890575 @default.
• W3109023079 hasRelatedWork W1774769 @default.
• W3109023079 hasRelatedWork W6726199 @default.
• W3109023079 isParatext "false" @default.
• W3109023079 isRetracted "false" @default.
• W3109023079 magId "3109023079" @default.
• W3109023079 workType "article" @default.